Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $143,025.10 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 3,310 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $143,025.10. Following the sale, the senior vice president now owns 84,585 shares in the company, valued at approximately $3,654,917.85. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total value of $13,941.18.
• On Monday, August 5th, Paula Green sold 1,137 shares of Twist Bioscience stock. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41.

Twist Bioscience Stock Up 1.3 %

Shares of NASDAQ:TWST traded up $0.55 during mid-day trading on Friday, hitting $43.34. 341,909 shares of the company traded hands, compared to its average volume of 783,825. The stock has a 50-day moving average price of $45.23 and a two-hundred day moving average price of $43.56. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience’s revenue was up 27.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) earnings per share. On average, sell-side analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TWST. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. TD Cowen raised their target price on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. The Goldman Sachs Group boosted their target price on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.63.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. grew its holdings in shares of Twist Bioscience by 1,021.8% in the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares in the last quarter. Fred Alger Management LLC grew its stake in Twist Bioscience by 720.7% in the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares during the period. Victory Capital Management Inc. increased its position in shares of Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after purchasing an additional 300,891 shares during the last quarter. Farallon Capital Management LLC bought a new stake in shares of Twist Bioscience during the 2nd quarter worth $9,462,000. Finally, Driehaus Capital Management LLC boosted its holdings in shares of Twist Bioscience by 63.0% in the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after buying an additional 150,260 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.